Definium's Experimental Depression Drug Hits the Mark in Phase 3
Fantastic news today for Definium Therapeutics!
The company just reported positive Phase 3 results for DT120, its experimental treatment for major depressive disorder.
The study evaluated a single dose of DT120, an orally disintegrating tablet containing a pharmaceutically optimized formulation of LSD. After six weeks, patients receiving DT120 showed significantly greater improvement in depression symptoms than those receiving a placebo, meeting the trial’s primary endpoint. The treatment produced an 8.1-point advantage over placebo on the Montgomery-Åsberg Depression Rating Scale (MADRS), a commonly used measure of depression severity.
That’s a meaningful result in a disease area where many patients cycle through multiple medications without finding lasting relief.
What makes DT120 particularly interesting is that it was administered as a single dose. Most antidepressants must be taken daily and often require weeks before patients experience meaningful benefits. Definium’s data suggest a single treatment may be capable of delivering improvements that persist for weeks afterward.
The company also reported that side effects were generally mild to moderate, with no new safety concerns emerging during the trial. Patients were typically discharged the same day after treatment.
Definium’s Phase 3 success represents one of the strongest late-stage datasets yet reported for a psychedelic-based treatment. The company is already running additional Phase 3 studies, and if those results are consistent, DT120 could move significantly closer to FDA approval.
Of course, one successful study doesn’t guarantee approval. Regulators will still want to see additional data, and commercialization presents its own challenges. But after years of speculation about the potential of psychedelic medicine, Definium has now delivered the kind of late-stage clinical evidence researchers have been waiting for.